secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001171843-24-001127
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose receives Nasdaq deficiency notice for stock issuance without shareholder approval
--------------------------------------------------------------------------------

- Nasdaq notified Aptose on Feb 29, 2024 that the Hanmi stock issuance violated Rule 5635(d) by issuing >20% of common shares at a discount without shareholder approval.
- Company has 45 days, until April 14, 2024, to submit a plan to regain compliance.
- If Nasdaq accepts the plan, an extension of up to 180 days from the deficiency letter may be granted.
- No immediate effect on listing; APTO continues trading on Nasdaq and TSX under symbol APS.
- Aptose believes the transaction complied with rules and intends to work with Nasdaq, but no assurance of regaining compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184324001127/0001171843-24-001127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184324001127/f8k_030124.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-001127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer